Predictive Oncology (NASDAQ: POAI), an oncology and cancer research company using big data and machine learning to improve pharmaceutical development and predictive treatment outcomes, today announced the launch of a website that emphasizes its role in advancing its mission. According to the update, the website features information about Predictive Oncology and its subsidiaries, which are all integral to the overarching goal of eliminating cancer by predicting treatment outcomes and aiding in the development and optimization of cancer drugs. “The website redesign is really intended to showcase the great work that all these teams have been doing and emphasize what they’re all contributing to the same grand mission under the Predictive Oncology banner,” said J. Melville Engle, CEO and chairman of the board of Predictive Oncology. “Putting an end to cancer is a team effort. We need the analytical capabilities of Helomics and TumorGenesis to help expedite the development of new cancer treatments and we need the expertise of Soluble Biotech to optimize those treatments. Each is mission-critical to our end goal of equipping healthcare providers with what they need to take the fight to cancer and win.”
To view the full press release, visit https://ibn.fm/IABIu
About Predictive Oncology Inc.
Predictive Oncology is a knowledge-driven company focused on applying artificial intelligence (“AI”) to develop personalized cancer therapies, which can lead to more effective treatments and improved patient outcomes. Using artificial intelligence, Predictive Oncology utilizes a database of 150,000+ cancer tumors, categorized by patient type, against drug compounds to determine optimal therapies to be used to ultimately eliminate cancer. As the drug discovery community realizes, a genomics-based approach to cancer research and drug development is insufficient to achieve the promise of personalized therapeutics. Predictive Oncology instead takes a multiomic approach, which considers the vast multitude of factors that make each cancer unique. Rather than operating based on the equivalent of a birds’ eye view, Predictive Oncology makes possible a more personalized and effective approach to cancer research and treatment. For more information, visit the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
